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INTRODUCTION: WHO grade II and III meningiomas in therapeutic failure are a real therapeutic challenge with a rate of progression-free survival at 6 months closed to 10%. The results of our in vitro studies have demonstrated an additive antiproliferative effect of octreotide and everolimus on meningiomas in primary culture. These results led us to test this combination within the PHRC K-2013 targeting meningiomas with therapeutic failure despite multiple surgeries and radiation therapy.
MATERIALS AND METHODS: 20 patients were included in this twocenter phase II study in 18 months. The eligibility criteria include meningiomas with treatment failure after surgery and radiotherapy and radiological progression documented before inclusion. The expected duration of treatment is one year. The primary endpoint is the PFS6, but the PFS average, the rate of tumor growth, the overall survival and side effects will also be assessed. A central review of imaging is planned. The success criterion of this study is to observe a PFS6> 40%.
RESULTS: 20 patients were included in less than a year (18% grade I, grade II 70%, and 12% of grade III). To date, 78 cycles were performed. We note 3 cases of discontinuation for poor tolerance (1 case of 2 drugs discontinuation, 1 case of octreotide discontinuation and 1 case of everolimus discontinuation), and 1 case of discontinuation for progression at 3 months. Among the 6 patients who continued combination therapy 6 months or more, the treatment was discontinued in 1 case for progression.
DISCUSSION: The rapid inclusion highlights a real medical need and the feasibility of this protocol. Tolerance of everolimus-octreotide combination seems acceptable on these preliminary results. Further analysis is required to precise the activity of this combination. RESULTS: Of the 17 patients enrolled, 9 had isolated peripheral involvement, 3 had isolated central involvement and 5 had mixed central and peripheral involvement. Fourteen patients had anti-Hu antibodies, 2 patients anti-CV2 and 1 anti-Yo antibodies. Thirteen patients had an associated neoplasm, which in 10 cases was a small-cell lung cancer; in the remaining 4 patients no tumor was detected during follow-up. Mean delay from neurological symptom onset to the start of IVIg treatment was 2.8 months.
OS6.7 EARLY INTRAVENOUS IMMUNOGLOBULIN TREATMENT
Ten patients concomitantly received antitumoral treatments. At 3 months, 3 patients had improved, 3 patients had deteriorated and 7 patients had stabilized. Primary outcome could not be assessed in 4 patients: 2 patients died prematurely, 1 dropped out and 1 interrupted IVIg treatment after one cure due to cutaneous toxicity. At 6 months, 9 out of the 13 patients with cancer were still alive, 7 of which were in tumor remission.
CONCLUSIONS: IasON was the first prospective trial to assess the efficacy of IVIg treatment in patients with PNS. IVIg treatment was in general well tolerated and only one patient had serious toxicity resulting in treatment discontinuation. At 3 months, a higher proportion of patients improved compared to previous studies on IVIg. This could be the result of both the earlier IVIg administration in our series and the recent advances made in cancer care, allowing a faster achievement of tumor remission. The timeliness of treatment is probably a key factor to obtain a clinical response in PNS and this should be highly regarded by future studies.
BACKGROUND: Glioblastoma multiforme (GBM) is associated with a poor prognosis and patients rely heavily on family caregivers for physical and emotional support. The capability and mental health of family caregivers may influence their ability to provide care and affect patient outcomes. We aimed to investigate whether caregivers' anxiety, depressive symptoms, burden and mastery influenced survival in a sample of patients newly diagnosed with GBM.
METHODS: Baseline data from caregiver-patient dyads participating in a NIH funded large, longitudinal study were used. Cox regression analyses were performed to determine whether caregiver anxiety (Profile of Mood States-Anxiety), depressive symptoms (Center for Epidemiologic StudiesDepression), burden (Caregiver Reaction Assessment), and feelings of mastery (Mastery Scale) predicted GBM patient survival time after controlling for known covariates (patient age, performance status, type of surgery, and postsurgical treatment).
RESULTS: In total, 88 caregiver-patient dyads were included. Median overall survival for the sample was 14.5 months (range 0-88 months). After controlling for covariates, mastery was predictive of patient survival. With each unit increase in mastery, there was a 16.1% risk reduction of patient death (95% confidence interval: 0.771-0.913, P<0.001).
CONCLUSIONS: Our results are among the first to explore the impact of family caregiving for GBM patients' outcomes. If these results are supported in other studies, providing neuro-oncology caregivers with more structured support and guidance in clinical practice have the potential to improve caregivers' feelings of mastery, influencing patients' wellbeing for the better. Brain metastases (BM) are an increasing challenge. Insight in the pathology of the brain metastatic cascade, and in particular in the characteristics of the BM initiating cells can help to identify new treatment targets. PHK26 membrane dye was used in stably GFP expressing human breast cancer to differentiate slow from fast cycling cells by membrane signal intensity changes using multiphoton laser scanning microscopy, both in vitro and in vivo. The heterogeneous population of fast and slow cycling cells as well as resting cells was injected intracardially and followed with in vivo repetitive multiphoton laser microcopy via a chronic intracranial window. Here, slow cycling cells, representing only 16% of the entire cell population, were the only ones that mastered all steps of the brain metastatic cascade (0% marcometastasis formation after intravascular arrest of fast cycling cells vs. 6.15% marcometastasis formation after intravascular arrest of slow cycling cells; p<0.001), namely intravascular arrest, extravasation, perivascular survival, and marcometastasis outgrowth. These slow cycling cells showed a high overlap with established markers for tumor stem-like cells, like Oct4/Sox2, Notch and WNT, and also (but less) with low 26S proteasome activity. Illumina gene expression profiling of slow versus fast cycling JIMT1 breast cancer cells revealed up-regulation of N-Myc down regulated gene (NDGR1). Knock down of NDRG1 resulted in complete inhibition of BM formation by preventing successful colonization of the perivascular niche. In conclusion, slow cycling cells resemble the population of BM initiating cells. Increased NDRG1 expression is a characteristic of slow cycling cells, and is a pivotal molecular precondition for successful BM formation that might serve as a potential target for BM prevention or treatment. INTRODUCTION: Treatment options for brain metastases (BM) and leptomeningeal carcinomatosis (LC) are limited due to the inability of most anti-cancer agents to cross the blood-brain barrier (BBB) and the bloodcerebrospinal fluid barrier (BCB). ANG1005 is a novel taxane derivative, consisting of 3 paclitaxel molecules covalently linked to Angiopep-2, a peptide designed to cross the BBB/BCB via the LRP-1 transport system and to penetrate malignant cells. MATERIALS AND METHODS: Adult patients with measurable recurrent BM from breast cancer, with or without LC, were enrolled in this multicenter, open-label study (n=72 safety population; n=58 efficacy population). ANG1005 was administered IV at 600 mg/m 2 q3w. HER2+ patients were allowed to continue trastuzumab +/-pertuzumab for systemic disease control. Intracranial (IC) response was assessed by Gd-MRI using CNS RECIST 1.1 and extracranial response was evaluated per RECIST 1.1. RESULTS: Median age was 47.5 (26-76) years. Safety profile was similar to that of paclitaxel with myelosuppression as the predominant toxicity. Patients received a median of 6 (1-29) prior therapies for breast cancer, including 86% with prior taxane treatment. To treat their BM, 84% had prior cranial surgery and/or radiation, and 18% of the patients had prior systemic therapies. Clinical benefit (best IC PR + SD) was seen in 71% of the patients. Best IC response in the efficacy population included 8/58 (14%) patients with PRs [3 (5%) confirmed PRs] and 33/58 (57%) with SD. For evaluable patients with LC, best IC responses included 5/23 (22%) PRs [2 (9%) confirmed PRs] and 12/23 (52%) SDs. Importantly, Kaplan-Meier estimated median OS was 34.6 weeks (95% CI 24.1-40.9) for patients with LC from first ANG1005 treatment. Improvement of clinical symptoms post-ANG1005 treatment was seen, including in patients with LC. Completed extracranial tumor assessments in 30 evaluable patients with extracranial lesions showed disease control in 90% of the patients [1 (3%) CR, 2 (7%) PRs and 24 (80%) SDs]. Furthermore, 93% of these patients with extracranial disease control had prior taxane therapy.
OS7.2 A PHASE II STUDY OF ANG1005, A NOVEL BBB/BCB PENETRATANT TAXANE IN PATIENTS WITH RECURRENT BRAIN METASTASES AND LEPTOMENINGEAL CARCINOMATOSIS FROM BREAST CANCER
CONCLUSIONS: Anti-tumor activity with ANG1005 was seen both intracranially and extracranially. Response was notable in patients with LC, resulting in prolonged OS compared to historical control and improvement of clinical symptoms in these poor prognosis patients. The estimated median OS for the LC patients of 8 months, following ANG1005 treatment, considerably exceeds the historical median of two months, if untreated, and 3 to 4 months, following aggressive therapy. BACKGROUND: Brain metastases (BM) occur in up to 50% of patients suffering from metastatic malignant melanoma (MM), and up to 30% of those suffering from HER2 positive and triple negative breast cancer. BM are associated with high morbidity and mortality due to limited treatment strategies. Therefore, a deeper understanding of the key factors involved in the brain metastatic cascade are needed to identify targets for preventive strategies. Platelets and the coagulation system are interesting candidates in this respect. However, the impact of thrombus formation and von Willebrand (vWF) factor fibers on the brain metastatic cascade has not been investigated so far.
OS7.3 IMPACT OF PLATELETS AND COAGULATION FACTORS
METHODS: Multiphoton laser scanning microscopy (MPLSM) via a chronic cranial window in mice was used to investigate the single steps of BM formation after intracardial injection of A2058 and H1 (human melanoma) and Jimt1 br (human breast cancer), stably expressing green or red fluorescent protein. I.v. Rhodamin 6G dye injection before imaging was used to visualize thrombocytes in thrombus formation and FITC labeled antivWF was used to visualize vWF fibers in vivo.
RESULTS: It was possible to establish the first long-term imaging method that allows to study the entire brain metastatic cascade and platelet / vWF accumulation simultaneously. More than 60% of tumor cells demonstrated platelet aggregation at the site of their arrest in brain microvessels, particularly just before the time point of extravasation. The ability to successfully extravasate and grow to a micrometastasis in the brain parenchyma was increased in cells with surrounding thrombus formation, indicating that early clot formation fosters several steps of the brain metastatic cascade. Ongoing experiments investigate the impact of vWF on extravasation and micrometastasis outgrowth. Finally, we will present data of how anticoagulants (heparin) and dual platelet inhibition can prevent extravasation into the brain, and later outgrowth to a clinically relevant macrometastasis.
CONCLUSION: Thrombus formation seems to facilitate extravasation of brain metastasis initiating cells and is therefore an early key factor of the brain metastatic cascade. Further experiments are on-going to investigate the potential of clot-inhibiting agents for BM prevention.
